These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23070394)

  • 1. [Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report].
    Kamiyama Y; Iguchi R; Makino Y; Kanamaru S; Ito N; Imanaka K
    Hinyokika Kiyo; 2012 Sep; 58(9):515-8. PubMed ID: 23070394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : report of a case].
    Kageyama S; Iwaki H; Masuda Y; Yoshida T; Narita M; Okada Y
    Hinyokika Kiyo; 2011 Apr; 57(4):203-7. PubMed ID: 21646852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
    Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
    Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
    Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
    Fujita M; Goto T; Uchida K; Saiki S; Arima R
    Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
    Zhao W; Deng H; Jie P; Qing C; Zhang X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy].
    Kanda S; Narita S; Komine N; Kitajima S; Yamauchi M; Sugita A; Saito Y; Habuchi T
    Hinyokika Kiyo; 2016 Dec; 62(12):647-650. PubMed ID: 28103659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nuclear medicine therapy of bone metastases].
    Kimmig B; Hermann HJ; Kober B
    Rontgenblatter; 1983 Jul; 36(7):216-9. PubMed ID: 6622951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival.
    Kuroda I
    Ann Nucl Med; 2014 Jan; 28(1):11-6. PubMed ID: 24127064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer involving bilateral seminal vesicles along with bone and testicular metastases: a case report.
    Gao Q; Chen J; Dai Y
    J Med Case Rep; 2018 Mar; 12(1):72. PubMed ID: 29519246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation.
    Zagars GK; Pollack A; von Eschenbach AC
    Cancer; 1997 Aug; 80(4):764-75. PubMed ID: 9264361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy.
    Leong C; McKenzie MR; Coupland DB; Gascoyne RD
    J Nucl Med; 1994 Oct; 35(10):1662-4. PubMed ID: 7931669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.